Philips acquires Remote Diagnostic Technologies

« Back to Industry News

25/06/2018

Royal Philips (NYSE:PHG) said on 15 June it acquired U.K.-based Remote Diagnostic Technologies for an undisclosed amount.

Remote Diagnostic Technologies develops cardiac therapy, data management and monitoring solutions for the pre-hospital market, and has a portfolio of connected emergency care solutions that Amsterdam-based Philips said will complement its therapeutic care biz.

“We are committed to investing in and expanding our resuscitation and emergency care offering, and with the acquisition of RDT we can boost our capabilities and portfolio in this vital area of healthcare. With its focus on the pre-hospital market, RDT’s portfolio of emergency care solutions will enable Philips to grow its presence in this market, as we further build our health technology portfolio and extend the range of connected, data-driven solutions we offer to our customers,” Philips therapeutic care biz lead Arman Voskerchyan said in a prepared statement.

With the acquisition, Philips will pick up RDT’s ambulance and emergency responder products, including the Tempus ALS modularized monitor and defibrillator, the company said.

RDT employs approximately 100 individuals and is headquartered in Hampshire, U.K., but has connections with Europe and North America. RDT will operate within the company’s therapeutic care biz group alongside Philips existing emergency care & resuscitation and hospital respiratory care biz.

“We are delighted to become part of Philips and continue on our journey that began over 20 years ago. Our mission is very much aligned with Philips’ own, as we are committed to transforming the delivery of care and improving patient outcomes driven by customer-focused innovation. Together, we will continue to enable prehospital caregivers to make a real difference to patient outcomes everywhere,” RDT CEO Graham Murphy said in a press release.

Earlier this month, Philips said it signed a deal to acquire image-guided cardiac arrhythmia treatment dev EPD Solutions for $293 million (EU €250 million) upfront with a possible additional $246.2 million (EU €210 million) upon completion of the deal based on certain milestones.


Click here to view the related article.

« Back to Industry News